Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 3/20 | 0.37 |
| ▸ | PKLR | P30613 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24631196 | 1.00 | BRD4 (0.38) | BRD4LMNASMN1; SMN2PKMPKLR | |
| SCHEMBL30868583 | 0.83 | LMNA (0.42) | BRD4LMNASMN1; SMN2PKMKIF11 | |
| SCHEMBL30868578 | 0.83 | LMNA (0.48) | LMNASMN1; SMN2PKMABL1MAPK1 | |
| SCHEMBL24631313 | 0.83 | LMNA (0.48) | LMNASMN1; SMN2PKMABL1MAPK1 | |
| SCHEMBL24631405 | 0.83 | LMNA (0.42) | BRD4LMNASMN1; SMN2PKMKIF11 | |
| SCHEMBL24631163 | 0.76 | KIF11 (0.45) | BRD4PKMPKLRKIF11 | |
| SCHEMBL30868613 | 0.76 | KIF11 (0.45) | BRD4PKMPKLRKIF11 | |
| SCHEMBL30868540 | 0.75 | BRD4 (0.45) | BRD4MAPK1KMT2A | |
| SCHEMBL27170917 | 0.75 | BRD4 (0.45) | BRD4MAPK1KMT2A | |
| SCHEMBL30868560 | 0.72 | BRAF (0.38) | BRD4LMNASMN1; SMN2MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083903-A1 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | MERCK SHARP & DOHME LLC (US) | 2024-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083903-A1 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | TEAD2, TEAD3, TEAD4 | BRD4 161/4885LMNA 4282/4885SMN1; SMN2 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.